The House Democratic leadership is proposing a $2,000 catastrophic cap in Medicare Part D as part of its year-end push on drug pricing legislation.
That stands out as one proposal in the newly unveiled HR 3 that the pharmaceutical industry could support. While it may seem perverse to look for silver linings in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?